GlassScriptPhysician profile
Sharmini Elizabeth Long
NPI 1679793699
$5,887.36
in general payments reported to CMS, 2019-2025
43 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $408 · 2021: $711 · 2022: $942 · 2023: $1,198 · 2024: $1,281 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $65.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.12 |
| Education | $65.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,063.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $726.60 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Radius Health, INC. | $368.02 | 2021-2025 | Tymlos |
| Antares Pharma, INC. | $336.73 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $328.06 | 2019-2025 | |
| Amgen INC. | $268.99 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $232.06 | 2019-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.71 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $218.30 | 2020-2025 | |
| Amphastar Pharmaceuticals, INC. | $164.00 | 2024-2025 | Baqsimi |
| Mannkind Corporation | $150.85 | 2020-2024 | Afrezza |
| Medtronic, INC. | $130.94 | 2021-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $121.81 | 2022-2025 | Strensiq |
| Chiesi USA, INC. | $115.61 | 2025 | Mycapssa |
| Abbott Laboratories | $114.27 | 2022-2025 | Freestyle Libre 3, Eterna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $101.35 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $96.32 | 2024 | |
| Halozyme INC | $88.45 | 2023 | |
| Medtronic Minimed, INC. | $86.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.04 | 2021-2023 | |
| Insulet Corporation | $83.16 | 2020-2022 | |
| Pfizer INC. | $81.10 | 2021-2024 | |
| Ibsa Pharma INC. | $71.66 | 2019-2023 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $58.50 | 2024-2025 | |
| Astellas Pharma US INC | $56.40 | 2023-2024 | Veozah |
| Beta Bionics, INC. | $55.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astrazeneca Pharmaceuticals LP | $53.96 | 2021-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $45.87 | 2023 | Recorlev, Gvoke Hypopen |
| Sequel Med Tech, LLC | $42.59 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $34.95 | 2023-2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $33.28 | 2023-2025 | NP Thyroid 60 |
| Dexcom, INC. | $30.79 | 2020-2024 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $27.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2023 | Gattex |
| Recordati_rare_diseases_inc. | $22.68 | 2024 | Signifor Lar, Isturisa |
| Janssen Pharmaceuticals, INC | $21.47 | 2019 | |
| Kyowa Kirin, INC. | $21.01 | 2023 | Crysvita |
| Lifescan, INC. | $20.08 | 2021 | |
| Becton, Dickinson and Company | $18.74 | 2020 | |
| Currax Pharmaceuticals LLC | $15.40 | 2025 | Contrave |
| Senseonics, Incorporated | $14.00 | 2019 | |
| Clarus Therapeutics INC. | $13.54 | 2021 | |
| Cequr Corporation | $12.58 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharmini Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.